Sugi Predict

Sugi Predict / Compounds / SCHEMBL219601

SCHEMBL219601

SCHEMBL219601

CS(=O)(=O)Nc1ccc(Br)cc1C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.71
▸ METAP2 P50579 4/20 0.65
▸ APEX1 P27695 1/20 0.56
▸ KDM1A O60341 1/20 0.53
▸ KMT2A Q03164 4/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ POLB P06746 1/20 0.51
▸ KDM4E B2RXH2 3/20 0.49
▸ TDP1 Q9NUW8 2/20 0.49
▸ AKR1C4 P17516 1/20 0.48
▸ AKR1C3 P42330 1/20 0.48
▸ AKR1C2 P52895 1/20 0.48
▸ AKR1C1 Q04828 1/20 0.48
▸ PLA2G1B P04054 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ ATG4B Q9Y4P1 1/20 0.48
▸ GLA P06280 1/20 0.47
▸ SLC22A12 Q96S37 1/20 0.47
▸ CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2365878 0.87 ALDH1A1 (0.58) ALDH1A1METAP2APEX1KMT2AKDM4E
SCHEMBL2738026 0.84 ALDH1A1 (0.63) ALDH1A1METAP2KMT2APOLBKDM4E
SCHEMBL31046908 0.83 METAP2 (0.60) ALDH1A1METAP2APEX1KDM1AKMT2A
SCHEMBL23141230 0.83 METAP2 (0.60) ALDH1A1METAP2APEX1KDM1AKMT2A
SCHEMBL21384564 0.81 METAP2 (0.56) ALDH1A1METAP2APEX1KDM1AKMT2A
SCHEMBL222213 0.81 METAP2 (0.68) ALDH1A1METAP2KMT2AMEN1KDM4E
SCHEMBL7117439 0.80 SLC10A2 (0.63) ALDH1A1KMT2AMEN1POLBKDM4E
SCHEMBL13754023 0.80 ALDH1A1 (0.59) ALDH1A1METAP2KDM4EHPGDSLC22A12
SCHEMBL221627 0.80 KMT2A (0.49) ALDH1A1METAP2APEX1KMT2AMEN1
SCHEMBL30100431 0.80 ACLY (0.66) ALDH1A1METAP2KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3792251-B1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS ELANCO TIERGESUNDHEIT AG (CH) 2024-02-14 — — EP disclosed
WO-2022109148-A1 SMALL MOLECULE INHIBITORS OF SARS-COV-2 INFECTIONS THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2022-05-27 — — WO disclosed
EP-3186227-B1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS ELANCO TIERGESUNDHEIT AG (CH) 2021-03-24 — — EP disclosed
EP-3792251-A1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS Elanco Tiergesundheit AG (CH) 2021-03-17 — — EP disclosed
CN-106660961-B Sulfonylaminobenzamide compounds as anthelmintics 瑞士伊兰科动物保健有限公司 2020-05-05 — — CN disclosed
US-10464889-B2 Sulfonylaminobenzamide compounds as anthelmintics ELANCO TIERGESUNDHEIT AG (US) 2019-11-05 — — US disclosed
US-20180319741-A1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS ELANCO TIERGESUNDHEIT AG (US) 2018-11-08 — — US disclosed
US-20180298011-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. 2018-10-18 — — US disclosed
US-9957275-B2 Pyrazolo[1,5-A]pyrimidines for antiviral treatment GILEAD SCIENCES, INC. (US) 2018-05-01 — — US disclosed
US-9957275-B2 Pyrazolo[1,5-A]pyrimidines for antiviral treatment GILEAD SCIENCES, INC. (US) 2018-05-01 — — US disclosed
US-8486938-B2 Pyrazolo[1,5-a]pyrimidines for antiviral treatment GILEAD SCIENCES, INC. (US) 2013-07-16 — — US disclosed
WO-2013096681-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS GILEAD SCIENCES, INC. (US) 2013-06-27 — — WO disclosed
US-20130164280-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS GILEAD SCIENCES, INC. (US) 2013-06-27 — — US disclosed
US-20130164280-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS GILEAD SCIENCES, INC. (US) 2013-06-27 — — US disclosed
EP-2585467-A1 PYRAZOLO [1, 5 -A]PYRIMIDINES AS ANTIVIRAL AGENTS Gilead Sciences, Inc. (US) 2013-05-01 — — EP disclosed
US-20120003215-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2012-01-05 — — US disclosed
US-20120003215-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2012-01-05 — — US disclosed
US-20120003215-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2012-01-05 — — US disclosed
WO-2011163518-A1 PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS GILEAD SCIENCES, INC. (US) 2011-12-29 — — WO disclosed
WO-2011163518-A1 PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS GILEAD SCIENCES, INC. (US) 2011-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120003215-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT TYMP, ZC3HAV1, TYMS ALDH1A1 1823/4885METAP2 1647/4885APEX1 1758/4885
US-20130164280-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS TYMP, ZC3HAV1, TYMS ALDH1A1 1436/4885METAP2 3034/4885APEX1 1732/4885
US-10464889-B2 Sulfonylaminobenzamide compounds as anthelmintics PKD2, CATSPER1, ATP1B2 ALDH1A1 1120/4885METAP2 242/4885APEX1 4697/4885
US-20180319741-A1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS PKD2, CATSPER1, PKD1 ALDH1A1 1365/4885METAP2 341/4885APEX1 4680/4885
US-20180298011-A1 PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT TYMP, ZC3HAV1, TYMS ALDH1A1 1823/4885METAP2 1647/4885APEX1 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.